Abstract
Acquired hemophilia A (AHA) is a rare condition that may be drug-induced. In this case report, we describe a patient who presented with extensive subcutaneous bleeding three years after beginning treatment with adalimumab for necrotizing scleritis. His workup was compatible with drug-induced AHA. He was treated with high-dose corticosteroids, cyclophosphamide, and rituximab. Adalimumab was discontinued. We present this case as an example of a rare, but potentially life-threatening, complication of adalimumab.
Original language | English (US) |
---|---|
Pages (from-to) | 294-296 |
Number of pages | 3 |
Journal | Ocular Immunology and Inflammation |
Volume | 30 |
Issue number | 2 |
DOIs | |
State | Published - 2022 |
Keywords
- Acquired hemophilia
- adalimumab
- anti-TNF-α
- blood coagulation disorders
- factor VIII inhibitor
- scleritis
ASJC Scopus subject areas
- Immunology and Allergy
- Ophthalmology